We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 01, 2022

Type 2 Diabetes in a High-Income Setting: Lifetime Risk, Life Expectancy, and Years of Life Lost

The Lancet Diabetes & Endocrinology


Additional Info

The Lancet Diabetes & Endocrinology
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study
Lancet Diabetes Endocrinol 2022 Sep 29;[EPub Ahead of Print], D Tomic, JI Morton, L Chen, A Salim, EW Gregg, ME Pavkov, M Arffman, R Balicer, M Baviera, E Boersma-van Dam, R Brinks, B Carstensen, JCN Chan, YJ Cheng, S Fosse-Edorh, S Fuentes, H Gardiner, HL Gulseth, R Gurevicius, KH Ha, A Hoyer, G Jermendy, A Kautzky-Willer, I Keskimäki, DJ Kim, Z Kiss, P Klimek, M Leventer-Roberts, CY Lin, P Lopez-Doriga Ruiz, AOY Luk, S Ma, M Mata-Cases, D Mauricio, S McGurnaghan, T Imamura, SK Paul, A Peeters, S Pildava, A Porath, C Robitaille, MC Roncaglioni, T Sugiyama, KL Wang, SH Wild, N Yekutiel, JE Shaw, DJ Magliano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading